As Oclaro (OCLR) Market Value Declined, Kopp Investment Advisors Trimmed Its Stake; Pfizer (PFE) Position Has Boosted by Wendell David Associates Inc

February 16, 2018 - By Adrian Erickson

Kopp Investment Advisors Llc decreased its stake in Oclaro Inc. (OCLR) by 6.49% based on its latest 2017Q3 regulatory filing with the SEC. Kopp Investment Advisors Llc sold 61,235 shares as the company’s stock declined 22.87% while stock markets rallied. The institutional investor held 882,831 shares of the technology company at the end of 2017Q3, valued at $7.62M, down from 944,066 at the end of the previous reported quarter. Kopp Investment Advisors Llc who had been investing in Oclaro Inc. for a number of months, seems to be less bullish one the $1.16 billion market cap company. The stock increased 1.18% or $0.08 during the last trading session, reaching $6.87. About 2.28 million shares traded. Oclaro, Inc. (NASDAQ:OCLR) has risen 92.74% since February 16, 2017 and is uptrending. It has outperformed by 76.04% the S&P500.

Wendell David Associates Inc increased its stake in Pfizer (PFE) by 26.39% based on its latest 2017Q3 regulatory filing with the SEC. Wendell David Associates Inc bought 12,322 shares as the company’s stock declined 3.45% while stock markets rallied. The institutional investor held 59,013 shares of the health care company at the end of 2017Q3, valued at $2.11 million, up from 46,691 at the end of the previous reported quarter. Wendell David Associates Inc who had been investing in Pfizer for a number of months, seems to be bullish on the $216.14B market cap company. The stock increased 1.54% or $0.55 during the last trading session, reaching $36.26. About 22.28 million shares traded or 6.84% up from the average. Pfizer Inc. (NYSE:PFE) has declined 2.76% since February 16, 2017 and is downtrending. It has underperformed by 19.46% the S&P500.

Wendell David Associates Inc, which manages about $664.31M and $565.93M US Long portfolio, decreased its stake in Exxonmobil (NYSE:XOM) by 7,865 shares to 135,541 shares, valued at $11.11M in 2017Q3, according to the filing. It also reduced its holding in Cvs Health (NYSE:CVS) by 6,915 shares in the quarter, leaving it with 25,000 shares, and cut its stake in Weingarten Realty (NYSE:WRI).

Since August 21, 2017, it had 0 buys, and 8 selling transactions for $12.56 million activity. The insider DAMELIO FRANK A sold 94,409 shares worth $3.21M. 8,000 Pfizer Inc. (NYSE:PFE) shares with value of $296,560 were sold by JOHNSON RADY A. Shares for $6.70M were sold by READ IAN C on Thursday, August 31. OLSON LAURIE J sold $263,693 worth of Pfizer Inc. (NYSE:PFE) on Monday, August 21. SUSMAN SALLY sold $1.34 million worth of stock.

Investors sentiment increased to 0.96 in 2017 Q3. Its up 0.02, from 0.94 in 2017Q2. It improved, as 53 investors sold PFE shares while 700 reduced holdings. 106 funds opened positions while 620 raised stakes. 4.06 billion shares or 0.86% more from 4.02 billion shares in 2017Q2 were reported. 37,841 are held by Hall Laurie J Trustee. Thompson Siegel And Walmsley Limited Liability reported 395,622 shares or 0.17% of all its holdings. Stillwater Limited Company holds 70,560 shares. Prudential Pcl invested in 1.03% or 9.17M shares. Bedrijfstakpensioenfonds Voor De Media Pno stated it has 0.59% of its portfolio in Pfizer Inc. (NYSE:PFE). Investec Asset North America reported 53,065 shares or 0.32% of all its holdings. Monroe Bancorp Tru Mi accumulated 45,944 shares or 0.51% of the stock. Natl Asset Inc stated it has 109,264 shares. Baldwin Brothers Ma stated it has 0.17% in Pfizer Inc. (NYSE:PFE). 39,235 were accumulated by Mackenzie Fincl Corporation. 10,402 were reported by Allsquare Wealth Mgmt Llc. Nbt Natl Bank N A holds 216,485 shares or 1.24% of its portfolio. Cedar Hill Associate Llc has 0.2% invested in Pfizer Inc. (NYSE:PFE) for 32,779 shares. General Amer Investors invested in 380,808 shares or 1.29% of the stock. Trillium Asset Mngmt Llc reported 11,715 shares.

Among 22 analysts covering Pfizer (NYSE:PFE), 10 have Buy rating, 1 Sell and 11 Hold. Therefore 45% are positive. Pfizer had 74 analyst reports since July 29, 2015 according to SRatingsIntel. On Thursday, July 20 the stock rating was downgraded by Credit Suisse to “Neutral”. As per Tuesday, November 3, the company rating was maintained by Argus Research. Cowen & Co maintained the stock with “Buy” rating in Monday, August 14 report. The rating was maintained by BMO Capital Markets on Tuesday, November 21 with “Buy”. The company was maintained on Wednesday, January 31 by Credit Suisse. Piper Jaffray maintained Pfizer Inc. (NYSE:PFE) rating on Friday, August 28. Piper Jaffray has “Overweight” rating and $48 target. UBS maintained Pfizer Inc. (NYSE:PFE) rating on Wednesday, November 1. UBS has “Buy” rating and $38.0 target. The rating was maintained by Jefferies on Tuesday, September 13 with “Buy”. The stock of Pfizer Inc. (NYSE:PFE) earned “Hold” rating by Jefferies on Wednesday, August 16. JP Morgan reinitiated Pfizer Inc. (NYSE:PFE) rating on Thursday, April 7. JP Morgan has “Overweight” rating and $38 target.

Among 18 analysts covering Oclaro Inc (NASDAQ:OCLR), 13 have Buy rating, 1 Sell and 4 Hold. Therefore 72% are positive. Oclaro Inc had 51 analyst reports since August 18, 2015 according to SRatingsIntel. Stifel Nicolaus maintained Oclaro, Inc. (NASDAQ:OCLR) on Wednesday, November 2 with “Buy” rating. Needham maintained Oclaro, Inc. (NASDAQ:OCLR) rating on Wednesday, February 3. Needham has “Buy” rating and $5 target. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, January 24. The rating was downgraded by Jefferies to “Hold” on Friday, February 2. The firm earned “Buy” rating on Tuesday, February 6 by FBR Capital. The firm has “Overweight” rating by Piper Jaffray given on Tuesday, February 23. The stock of Oclaro, Inc. (NASDAQ:OCLR) earned “Buy” rating by Cowen & Co on Thursday, August 3. The firm has “Buy” rating given on Tuesday, September 6 by Stifel Nicolaus. Northland Capital maintained the shares of OCLR in report on Thursday, November 2 with “Buy” rating. The rating was maintained by Piper Jaffray with “Buy” on Monday, February 5.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>